Keros Therapeutics, Inc.
KROSFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Keros Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 17, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| BlackRock, Inc. | 2026-03-31 | 2,411,793 | $26.6M | SEC filing |
| Nantahala Capital Management, LLC | 2026-03-31 | 1,360,419 | $15M | SEC filing |
| NATIXIS | 2026-03-31 | 100 | $1.1K | SEC filing |
| SJS Investment Consulting Inc. | 2026-03-31 | 8 | $89 | SEC filing |
| Invesco Ltd. | 2026-03-31 | 87,772 | $969K | SEC filing |
| Y-Intercept (Hong Kong) Ltd | 2026-03-31 | 164,483 | $1.82M | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 4,867 | $54K | SEC filing |
| Brevan Howard Capital Management LP | 2026-03-31 | 14,651 | $162K | SEC filing |
| PANAGORA ASSET MANAGEMENT INC | 2026-03-31 | 34,656 | $383K | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 97,318 | $1.07M | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 23,157 | $256K | SEC filing |
| Cornerstone Financial Management LLC | 2026-03-31 | 44 | $486 | SEC filing |
| Arax Advisory Partners | 2026-03-31 | 389 | $4.3K | SEC filing |
| Allworth Financial LP | 2026-03-31 | 287 | $3.17K | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 30,860 | Not shown | SEC filing |
| UBS Group AG | 2026-03-31 | 145,573 | $1.61M | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 5,406 | $59.7K | SEC filing |
| Smartleaf Asset Management LLC | 2026-03-31 | 394 | $4.21K | SEC filing |
| PRINCIPAL FINANCIAL GROUP INC | 2026-03-31 | 59,594 | $658K | SEC filing |
| CITIGROUP INC | 2026-03-31 | 2,208 | $24.4K | SEC filing |
- Each value is checked against Keros Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the value per share could not be confirmed against the share prices on file from within three months of the report date.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Keros Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-04-09 · ADAR1 Partners, LP: Larger than all 9 other insider purchases of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-15 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +1,000 | 10.19 | SEC filing |
| 2026-06-11 | Newton Charles W. · Director | Common Stock | S — Open market or private sale | −550 | 10.04 | SEC filing |
| 2026-06-04 | Seth Alpna · Director | Common Stock | S — Open market or private sale | −2,625 | 10.72 | SEC filing |
| 2026-06-04 | Knowles Julius · Director | Common Stock | S — Open market or private sale | −2,625 | 10.73 | SEC filing |
| 2026-06-04 | Farzan Nima · Director | Common Stock | S — Open market or private sale | −2,625 | 10.73 | SEC filing |
| 2026-05-15 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +1,000 | 10.58 | SEC filing |
| 2026-04-15 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +1,000 | 11.70 | SEC filing |
| 2026-03-09 | BIENAIME JEAN JACQUES · Director | Common Stock | P — Open market or private purchase | +2,000 | 11.21 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-03 | Seth Alpna · Director | Common Stock | A — Grant, award, or other acquisition | +7,142 | SEC filing |
| 2026-06-03 | GRAY MARY ANN · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,433 | SEC filing |
| 2026-06-03 | Seth Alpna · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,433 | SEC filing |
| 2026-06-03 | BIENAIME JEAN JACQUES · Director | Common Stock | A — Grant, award, or other acquisition | +7,142 | SEC filing |
| 2026-06-03 | Farzan Nima · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,433 | SEC filing |
| 2026-06-03 | Farzan Nima · Director | Common Stock | A — Grant, award, or other acquisition | +7,142 | SEC filing |
| 2026-06-03 | Knowles Julius · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,433 | SEC filing |
| 2026-06-03 | BIENAIME JEAN JACQUES · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,433 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-11-21 | GORDON CARL L · Director | Common Stock | D — Disposition to the issuer | −140,057 | SEC filing |
| 2025-11-21 | GORDON CARL L · Director | Common Stock | D — Disposition to the issuer | −74,465 | SEC filing |
| 2025-11-21 | Knowles Julius · Director | Common Stock | D — Disposition to the issuer | −191,527 | SEC filing |
| 2025-11-21 | Knowles Julius · Director | Common Stock | D — Disposition to the issuer | −130,494 | SEC filing |
| 2025-11-21 | ORBIMED ADVISORS LLC · Director | Common Stock | D — Disposition to the issuer | −140,057 | SEC filing |
| 2025-11-21 | ORBIMED ADVISORS LLC · Director | Common Stock | D — Disposition to the issuer | −74,465 | SEC filing |
| 2025-05-16 | ADAR1 Partners, LP · 10% owner | Put Option (obligation to buy) | E — Expiration of short derivative position | −836 | SEC filing |
| 2025-05-16 | ADAR1 Partners, LP · 10% owner | Put Option (obligation to buy) | E — Expiration of short derivative position | −178 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.